Sunday, June 13, 2021

Is the Sky the Limit For Fortress Biotech, Inc (FBIO) Stock?

Fortress Biotech, Inc. (FBIO) stock prices saw a 0.7% increase at market close, situating it at USD$5.48. This is the continuation of a consistent and gradual increase in FBIO stock price, with a more pronounced increase recently following certain developments.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



Acquisition of QBREXZA

Journey Medical Corporation, a partner company of FBIO, announced at the start of April 2021 that it would be expanding its footprint in dermatology with the acquisition of QBREXZA from Dermira, Inc. QBREXZA is the only FDA approved topical product for the treatment of primary axillary hyperhidrosis in users aged 9 and up. Having generated USD$24 million in net sales in 2020, one of QBREXZA’s key features is that it is a self-administered product. The expected closing date for this transaction is anticipated for Q2 of 2021.

Line of Credit


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Another positive development is that of the agreement between Journey Medical Corp. (Journey) and East West Bank (EWB) wherein EWB will provide Journey with USD$7.5 million in a line of credit for working capital. This LOC will be secured by Journey’s receivables and cash reserves. The agreement is set to expire in 3 years and carries an interest rate of either 4.25% or Prime Rate plus 1%, whichever is higher. Journey plans to use this capital for general corporate purposes, including expanding their product portfolio.

Steering Clear of a Public Offering

Investors typically favor self-sustained funding moves over dilutions of existing shares through a public offering, which commonly sees a selling off of shares by stockholders who don’t want the value of their shares to be diluted.

CUTX-101 progress

FBIO is also partnering up with SentynlTherepeutics and Cyprium Therapeutics in the current development of CUTX-101, a treatment for Menkes disease that is in Phase 3 of its clinical trials. The involved parties have entered a Development and Asset Purchase agreement. Rolling submission of the NDA will commence in the second half of 2021.

IV Tramadol Awaits FDA Approval

Avenue Therapeutics, Inc (ATXI), founded by FBIO, is currently awaiting FDA approval for its intravenous tramadol. Should it be approved, this product could be a viable alternative in the use of conventional opioids to treat patients with acute pain. Needless to say, FDA approval could prove to be very financially lucrative and many anticipate a surge in FBIO stock prices.

Latest news

 Hawaiian Holdings Inc. (HA): Weak Share Price A Buying Opportunity

Travel restrictions continue to be eased by Hawaii for tourists. Consequently, Hawaiian Airlines, owned by Hawaiian Holdings Inc. (NASDAQ: HA), stands to benefit as...

Set Your Sights On Conn’s Inc. (NASDAQ: CONN)’S Upside Potential

A furniture and home furnishings retailer, Conn's Inc. (NASDAQ: CONN), reported growth in sales in the first quarter. The company's performance surpassed analysts' predictions...

Does Investing In Roblox Corporation (RBLX) A Smart Move?

Roblox Corp. (NYSE: RBLX) released its first-quarter earnings report earlier this week. Growth in earnings and subscriber numbers are the main driving forces of...

Why is Sea Limited (SE) stock increasing rapidly?

Sea Limited (NYSE: SE), an online gaming, e-commerce, and digital payments company, reported strong earnings in the first quarter of 2021. Company revenue growth...

Related news

 Hawaiian Holdings Inc. (HA): Weak Share Price A Buying Opportunity

Travel restrictions continue to be eased by Hawaii for tourists. Consequently, Hawaiian Airlines, owned by Hawaiian Holdings Inc. (NASDAQ: HA), stands to benefit as...

Set Your Sights On Conn’s Inc. (NASDAQ: CONN)’S Upside Potential

A furniture and home furnishings retailer, Conn's Inc. (NASDAQ: CONN), reported growth in sales in the first quarter. The company's performance surpassed analysts' predictions...

Does Investing In Roblox Corporation (RBLX) A Smart Move?

Roblox Corp. (NYSE: RBLX) released its first-quarter earnings report earlier this week. Growth in earnings and subscriber numbers are the main driving forces of...

Why is Sea Limited (SE) stock increasing rapidly?

Sea Limited (NYSE: SE), an online gaming, e-commerce, and digital payments company, reported strong earnings in the first quarter of 2021. Company revenue growth...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.